NeuroSense Therapeutics

NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Image
NeuroSense Fights Nasdaq Delisting After Missing $35M Market Value Rule

Cambridge, Mass. – – October 03, 2026 -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) received a Nasdaq Staff Determination on October 03, 2026, confirming it failed to meet the $35 million minimum market value of listed securities (MVLS) requirement by its October 03, 2026 deadline, triggering a potential delisting from The Nasdaq Capital Market.

Company to appeal delisting threat before Nasdaq Hearings Panel

NeuroSense intends to timely request a hearing before a Nasdaq Hearings Panel under Nasdaq Listing Rule 5800 Series to seek additional time to regain MVLS compliance. A timely hearing request automatically stays any suspension of trading and the filing of a Form 25-NSE with the SEC while the Panel reviews the case. The Panel has discretion to grant an exception of up to 180 days from the October 1 Staff Determination date.

NeuroSense Cuts H1 Costs 28%, Targets Dec. 2026 Canada ALS Filing

Image
NeuroSense Cuts H1 Costs 28%, Targets Dec. 2026 Canada ALS Filing

Cambridge, Mass. – September 26, 2026 -- NeuroSense Therapeutics (NASDAQ: NRSN) cut operating expenses to $3.4 million in the first half of 2026, down from $4.7 million a year earlier, as the biotech pushes its ALS candidate PrimeC toward a Canadian regulatory filing targeted for December 2026.

NeuroSense trims R&D and G&A spending by double digits in H1 2026

Research and development expenses fell 16% to $2,102 thousand from $2,503 thousand, driven by lower subcontractor and consultant costs, partly offset by higher share-based payment expense. General and administrative expenses dropped 38.6% to $1,345 thousand from $2,189 thousand on reduced professional services spending.

NeuroSense Therapeutics Builds Clinical-Stage ALS Program Around Unmet Need and a New Therapeutic Perspective

SHERIDAN, WYOMING - April 14, 2026 - NeuroSense Therapeutics, a clinical-stage drug development company, is positioning itself to address what it characterizes as the "huge unmet need" among patients with amyotrophic lateral sclerosis (ALS). Founded specifically to tackle ALS from a differentiated angle, the company states that this "devastating disease must be addressed from a new perspective," signaling a departure from established therapeutic frameworks. NeuroSense maintains dedicated research and community programs and has published at least four updates between December 2024 and May 2025, indicating sustained development activity. The company's tagline, "New Hope on The Horizon," underscores a patient-focused posture embedded within its clinical-stage mandate.